Who Buys Oxaliplatin from India — 693 Importers Behind a $46.6M Market
India's oxaliplatin import market is served by 693 active buyers who collectively imported $46.6M across 3,081 shipments. FRESENIUS KABI DEUTSCHLAND GMBH (GERMANY) leads with a 21.5% market share, followed by OOO"JODAS EXPOIM" and PHARMACIE CENTRALE DES HOPITAUX. The top 5 buyers together control 40.2% of total import value, reflecting a moderately competitive buyer landscape.
Top Oxaliplatin Importers — Ranked by Import Value
FRESENIUS KABI DEUTSCHLAND GMBH (GERMANY) is the leading oxaliplatin importer from India, holding a 21.5% share of the $46.6M market across 3,081 shipments from 693 buyers. The top 5 buyers — FRESENIUS KABI DEUTSCHLAND GMBH (GERMANY), OOO"JODAS EXPOIM" (RUSSIA), PHARMACIE CENTRALE DES HOPITAUX (ALGERIA), YUSEN LOGISTICS BENELUX BELGIUM (BELGIUM), OOOJODAS EXPOIM (RUSSIA) — collectively control 40.2% of total import value.
Top Oxaliplatin Buyers & Importers
Ranked by import value · 693 active buyers · Indian Customs (DGFT) data
| # | Buyer & Formulations | Value | Suppliers | Share |
|---|---|---|---|---|
| 1 | FRESENIUS KABI DEUTSCHLAND GMBHGERMANY OXALIPLATIN KABI INJ.200MG/40ML VIAL B.NOXALIPLATIN KABI INJ.200MG/40ML VIAL(ITEOXITAN OXALIPLATIN INJ 150MG 30ML VIAL | $10.0M | 5 | 21.5% |
| 2 | OOO"JODAS EXPOIM"RUSSIA OXALIPLATIN CONCENTRATE FOR PREPARATIONHARMLESS MEDICINES-OXALIPLATIN CONCENTRA | $3.1M | 5 | 6.7% |
| 3 | PHARMACIE CENTRALE DES HOPITAUXALGERIA XYLATIN 100 (OXALIPLATIN INJECTION 100 MXYLATIN 100VLSXYLATIN 50 | $2.3M | 5 | 5.0% |
| 4 | YUSEN LOGISTICS BENELUX BELGIUMBELGIUM OXALIPLATIN INJ 100MG/20ML 1'S VL GB PACOXALIPLATIN INJ 100MG/20ML 1S VL GB PACOXALIPLATIN INJ 100MG/20ML 1'S VL GB (B | $2.2M | 5 | 4.8% |
| 5 | OOOJODAS EXPOIMRUSSIA OXALIPLATIN CONCENTRATE FOR PREPARATIONHARMLESS MEDICINES-OXALIPLATIN CONCENTRA | $1.0M | 5 | 2.2% |
| 6 | FRESENIUS KABI (THAILAND) LTDTHAILAND OXALIPLATIN KABI INJ.200MG/40ML VIAL B.NOXALIPLATIN KABI INJ.200MG/40ML VIAL(ITEOXITAN OXALIPLATIN INJ 150MG 30ML VIAL | $987.8K | 5 | 2.1% |
| 7 | MEITHEAL PHARMACEUTICALSUNITED STATES OXALIPLATIN INJECTIONOXALIPLATIN INJ USP 100MG/20ML VIALOXALIPLATIN INJ USP 5MG/ML-20ML-1S-MYLAN | $912.7K | 5 | 2.0% |
| 8 | OOO JODAS EXPOIMRUSSIA OXALIPLATIN CONCENTRATE FOR PREPARATIONHARMLESS MEDICINES-OXALIPLATIN CONCENTRA | $836.8K | 5 | 1.8% |
| 9 | FRESENIUS KABI COLOMBIA SASCOLOMBIA OXALIPLATIN KABI INJ.200MG/40ML VIAL B.NOXALIPLATIN KABI INJ.200MG/40ML VIAL(ITEOXITAN OXALIPLATIN INJ 150MG 30ML VIAL | $782.8K | 5 | 1.7% |
| 10 | XXIZEXXSERXXCE XXMPAXX BVBELGIUM OXALIPLATIN INJECTIONOXALIPLATIN INJ USP 100MG/20ML VIALOXALIPLATIN INJ USP 5MG/ML-20ML-1S-MYLAN | $702.1K | 5 | 1.5% |
| 11 | FRESENIUS KABI MALAYSIA SDN BHDMALAYSIA OXALIPLATIN KABI INJ.200MG/40ML VIAL B.NOXALIPLATIN KABI INJ.200MG/40ML VIAL(ITEOXITAN OXALIPLATIN INJ 150MG 30ML VIAL | $696.5K | 5 | 1.5% |
| 12 | DR.REDDY'S LABORATORIES CANADA INCCANADA | $649.2K | 5 | 1.4% |
| 13 | MYLAN INSTITUTIONAL INCUNITED STATES OXALIPLATIN INJECTIONOXALIPLATIN INJ USP 100MG/20ML VIALOXALIPLATIN INJ USP 5MG/ML-20ML-1S-MYLAN | $620.5K | 5 | 1.3% |
| 14 | C M C LTHAILAND OXALIPLATIN CONCENTRATE FOR PREPARATIONOXALIPLATIN INJECTIONXYLATIN 100 (OXALIPLATIN INJECTION 100 M | $620.1K | 5 | 1.3% |
| 15 | FRESENIUS KABI CHILE LTDA.CHILE OXALIPLATIN KABI INJ.200MG/40ML VIAL B.NOXALIPLATIN KABI INJ.200MG/40ML VIAL(ITEOXITAN OXALIPLATIN INJ 150MG 30ML VIAL | $606.1K | 5 | 1.3% |
Related Analysis
Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Which companies are buying Oxaliplatin — and from which countries?
Flow of Oxaliplatin exports from India: each country's share and the named importers behind the numbers
Oxaliplatin — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Market Analysis: Top Importing Countries & Their Importers
1Germany
Germany emerges as the first largest importing country, achieving a total trade value of $10.0M through 362 shipments. This represents a market share of 21.5% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Germany has a diverse importer base, with their top importers including:
• FRESENIUS KABI DEUTSCHLAND GMBH - $10.0M (100.0% of country's total business)
Key Insight: Germany demonstrates strong market positioning with an average shipment value of $27.7K, indicating premium pricing strategy compared to the market average of $15.1K.
Germany is a key market for Oxaliplatin imports, representing 21.5% of total trade value.
2Russia
Russia emerges as the second largest importing country, achieving a total trade value of $6.5M through 31 shipments. This represents a market share of 13.9% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Russia has a diverse importer base, with their top importers including:
• OOO"JODAS EXPOIM" - $3.1M (48.0% of country's total business)
• OOOJODAS EXPOIM - $1.0M (15.8% of country's total business)
• OOO JODAS EXPOIM - $836.8K (12.9% of country's total business)
• M/S. OOO JODAS EXPOIM.. - $484.5K (7.5% of country's total business)
Key Insight: Russia demonstrates strong market positioning with an average shipment value of $208.8K, indicating premium pricing strategy compared to the market average of $15.1K.
Russia is a key market for Oxaliplatin imports, representing 13.9% of total trade value.
3United States
United States emerges as the third largest importing country, achieving a total trade value of $4.4M through 24 shipments. This represents a market share of 9.4% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• MEITHEAL PHARMACEUTICALS - $912.7K (20.8% of country's total business)
• MYLAN INSTITUTIONAL INC - $620.5K (14.1% of country's total business)
• MYLAN INSTITUTIONAL INC. - $574.1K (13.1% of country's total business)
• MYLAN INSTITUTIONAL INC 2898 - $569.4K (13.0% of country's total business)
• FOSUN PHARMA USA INC - $508.0K (11.6% of country's total business)
• Rest of United States's importers - $1.2M (27.4% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $182.8K, indicating premium pricing strategy compared to the market average of $15.1K.
United States is a key market for Oxaliplatin imports, representing 9.4% of total trade value.
4Thailand
Thailand emerges as the fourth largest importing country, achieving a total trade value of $3.4M through 47 shipments. This represents a market share of 7.4% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Thailand has a diverse importer base, with their top importers including:
• FRESENIUS KABI (THAILAND) LTD - $987.8K (28.7% of country's total business)
• C M C L - $620.1K (18.0% of country's total business)
• FRESENIUS KABI THAILAND LTD - $511.4K (14.9% of country's total business)
Key Insight: Thailand demonstrates strong market positioning with an average shipment value of $73.2K, indicating premium pricing strategy compared to the market average of $15.1K.
Thailand is a key market for Oxaliplatin imports, representing 7.4% of total trade value.
5Algeria
Algeria emerges as the fifth largest importing country, achieving a total trade value of $2.9M through 61 shipments. This represents a market share of 6.3% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Algeria has a diverse importer base, with their top importers including:
• PHARMACIE CENTRALE DES HOPITAUX - $2.3M (80.3% of country's total business)
Key Insight: Algeria demonstrates strong market positioning with an average shipment value of $47.9K, indicating premium pricing strategy compared to the market average of $15.1K.
Algeria is a key market for Oxaliplatin imports, representing 6.3% of total trade value.
Buyer Segment Analysis
TransData Nexus Oxaliplatin buyer market intelligence
1Buyer Segment Analysis
The 693 buyers of Oxaliplatin imported from India can be categorized into several segments:
1. Distributors: Entities that purchase Oxaliplatin to supply to various healthcare providers.
2. Hospital Groups: Large healthcare institutions procuring directly for patient treatment.
3. Government Procurement Agencies: National bodies responsible for acquiring medicines for public healthcare.
4. Contract Manufacturers: Companies that produce pharmaceuticals on behalf of other firms.
Each segment exhibits distinct purchasing behaviors. Distributors often place frequent, moderate-sized orders to maintain a steady supply chain. Hospital groups and government agencies may engage in bulk purchasing through tenders to secure lower prices and ensure consistent availability. Contract manufacturers typically procure large quantities to meet production demands for their clients.
Country-Specific Import Regulations
TransData Nexus Oxaliplatin buyer market intelligence
1Country-Specific Import Regulations
- 1Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM)
- 2Import Registration Process: Requires submission of a marketing authorization application, including quality, safety, and efficacy data.
- 3Estimated Timeline: Approximately 7-12 months
- 4Import Tariff/Duty: Generally 0% for pharmaceuticals under HS Code 30049049
Germany:
- 1Regulatory Authority: Ministry of Health of the Russian Federation
- 2Import Registration Process: Involves state registration, including clinical trials and quality assessments.
- 3Estimated Timeline: Approximately 12-18 months
- 4Import Tariff/Duty: Approximately 5% for pharmaceuticals under HS Code 30049049
Russia:
- 1Regulatory Authority: Food and Drug Administration (FDA)
- 2Import Registration Process: Requires New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) approval.
- 3Estimated Timeline: Approximately 10-12 months
- 4Import Tariff/Duty: Generally 0% for pharmaceuticals under HS Code 30049049
United States:
- 1Regulatory Authority: Thai Food and Drug Administration (Thai FDA)
- 2Import Registration Process: Submission of a registration dossier, including clinical data and manufacturing details.
- 3Estimated Timeline: Approximately 6-12 months
- 4Import Tariff/Duty: Approximately 10% for pharmaceuticals under HS Code 30049049
Thailand:
- 1Regulatory Authority: Agence Nationale des Produits Pharmaceutiques (ANPP)
- 2Import Registration Process: Requires dossier submission, including quality, safety, and efficacy data.
- 3Estimated Timeline: Approximately 12-24 months
- 4Import Tariff/Duty: Approximately 15% for pharmaceuticals under HS Code 30049049
Algeria:
Demand Drivers & Market Opportunity
TransData Nexus Oxaliplatin buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Oxaliplatin is primarily driven by the prevalence of colorectal cancer, for which it is a standard chemotherapy treatment. According to the World Health Organization (WHO), colorectal cancer is among the top five most common cancers globally, with increasing incidence rates in both developed and developing countries. Government healthcare programs and the expansion of universal health coverage have further bolstered demand, as nations strive to provide comprehensive cancer care to their populations.
Additionally, Oxaliplatin's inclusion in the WHO Essential Medicines List underscores its importance in cancer treatment protocols, leading to its procurement through tender-based purchasing systems by various countries. The presence of 693 buyers across 123 countries indicates a robust and widespread market opportunity for Oxaliplatin, reflecting its critical role in global oncology treatment regimens.
Common Questions — Oxaliplatin Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest oxaliplatin buyer importing from India?
Based on import volume and value, FRESENIUS KABI DEUTSCHLAND GMBH (GERMANY) leads with $10.0M in imports and a 21.5% market share — the highest of any single oxaliplatin importer. OOO"JODAS EXPOIM" (RUSSIA) and PHARMACIE CENTRALE DES HOPITAUX (ALGERIA) are the next largest buyers.
QHow many companies buy oxaliplatin from India?
There are 693 active oxaliplatin buyers importing from India, with a combined market of $46.6M across 3,081 shipments to 123 countries. The top 5 buyers hold 40.2% of total import value, while the remaining 688 buyers handle the other 59.8%.
QWhich countries import the most oxaliplatin from India?
The top importing countries for oxaliplatin from India are Germany (21.5%), Russia (13.9%), United States (9.4%), Thailand (7.4%), Algeria (6.3%). These markets represent the largest demand centres for Indian pharmaceutical exports of oxaliplatin, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for oxaliplatin from India?
The average import transaction value for oxaliplatin from India is $15.1K, with an average unit price of $11.37 per unit. Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
Buyer Segment Analysis
TransData Nexus Oxaliplatin buyer market intelligence
1Buyer Segment Analysis
The 693 buyers of Oxaliplatin imported from India can be categorized into several segments:
1. Distributors: Entities that purchase Oxaliplatin to supply to various healthcare providers.
2. Hospital Groups: Large healthcare institutions procuring directly for patient treatment.
3. Government Procurement Agencies: National bodies responsible for acquiring medicines for public healthcare.
4. Contract Manufacturers: Companies that produce pharmaceuticals on behalf of other firms.
Each segment exhibits distinct purchasing behaviors. Distributors often place frequent, moderate-sized orders to maintain a steady supply chain. Hospital groups and government agencies may engage in bulk purchasing through tenders to secure lower prices and ensure consistent availability. Contract manufacturers typically procure large quantities to meet production demands for their clients.
Country-Specific Import Regulations
TransData Nexus Oxaliplatin buyer market intelligence
1Country-Specific Import Regulations
- 1Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM)
- 2Import Registration Process: Requires submission of a marketing authorization application, including quality, safety, and efficacy data.
- 3Estimated Timeline: Approximately 7-12 months
- 4Import Tariff/Duty: Generally 0% for pharmaceuticals under HS Code 30049049
Germany:
- 1Regulatory Authority: Ministry of Health of the Russian Federation
- 2Import Registration Process: Involves state registration, including clinical trials and quality assessments.
- 3Estimated Timeline: Approximately 12-18 months
- 4Import Tariff/Duty: Approximately 5% for pharmaceuticals under HS Code 30049049
Russia:
- 1Regulatory Authority: Food and Drug Administration (FDA)
- 2Import Registration Process: Requires New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) approval.
- 3Estimated Timeline: Approximately 10-12 months
- 4Import Tariff/Duty: Generally 0% for pharmaceuticals under HS Code 30049049
United States:
- 1Regulatory Authority: Thai Food and Drug Administration (Thai FDA)
- 2Import Registration Process: Submission of a registration dossier, including clinical data and manufacturing details.
- 3Estimated Timeline: Approximately 6-12 months
- 4Import Tariff/Duty: Approximately 10% for pharmaceuticals under HS Code 30049049
Thailand:
- 1Regulatory Authority: Agence Nationale des Produits Pharmaceutiques (ANPP)
- 2Import Registration Process: Requires dossier submission, including quality, safety, and efficacy data.
- 3Estimated Timeline: Approximately 12-24 months
- 4Import Tariff/Duty: Approximately 15% for pharmaceuticals under HS Code 30049049
Algeria:
Demand Drivers & Market Opportunity
TransData Nexus Oxaliplatin buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Oxaliplatin is primarily driven by the prevalence of colorectal cancer, for which it is a standard chemotherapy treatment. According to the World Health Organization (WHO), colorectal cancer is among the top five most common cancers globally, with increasing incidence rates in both developed and developing countries. Government healthcare programs and the expansion of universal health coverage have further bolstered demand, as nations strive to provide comprehensive cancer care to their populations.
Additionally, Oxaliplatin's inclusion in the WHO Essential Medicines List underscores its importance in cancer treatment protocols, leading to its procurement through tender-based purchasing systems by various countries. The presence of 693 buyers across 123 countries indicates a robust and widespread market opportunity for Oxaliplatin, reflecting its critical role in global oncology treatment regimens.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Buyer Identification: 693 global importers of Oxaliplatin identified from consignee fields in DGFT shipping bill records.
- 2.Import Value Analysis: Total import value aggregated from 3,081 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Geographic Distribution: Buyer imports distributed across 123 destination countries with market share per buyer calculated from capped values.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,081 Verified Shipments
693 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists